Abiopharma

Poseida Therapeutics (PSTX) Reports Q2 2022 Financial Results Poseida Therapeutics (PSTX) announced its financial results for the period ending Q2 2022. Key Financial Highlights:

• Revenue: 1435
• Net Income: Not disclosed
• EPS: Not disclosed
• Cash and equivalents: 183489
  • anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with development and regulatory approval of novel product candidates in the biopharmaceutical industry and the other risks described in Poseida's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Poseida undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. Poseida Therapeutics, Inc. Selected Financial Data (Unaudited) (In thousands, except share and per share amounts) STATEMENTS OF OPERATIONS Three Months Ended March 31, 2022